Cojuc-Konigsberg, GabrielGabrielCojuc-KonigsbergMoscona-Nissan, AlbertoAlbertoMoscona-NissanGuijosa, AlbertoAlbertoGuijosaMireles Dávalos, Christian D.Christian D.Mireles DávalosJiménez Martínez, María E.María E.Jiménez MartínezMújica Sánchez, Mario A.Mario A.Mújica SánchezHernández Huizar, Víctor F.Víctor F.Hernández HuizarDurán Barrón, Martha A.Martha A.Durán BarrónVillarreal Gómez, KarenKarenVillarreal GómezAndrade-Galindo, ReginaReginaAndrade-GalindoOrdóñez-Oviedo, MontserratMontserratOrdóñez-OviedoDeloya Brito, GreciaGreciaDeloya BritoBecerril Vargas, EduardoEduardoBecerril Vargas2023-10-112023-10-112023https://scripta.up.edu.mx/handle/20.500.12552/496710.1186/s12879-023-08486-4Background: Ventilator-Associated pneumonia (VAP) is one of the leading causes of morbidity and mortality in critically ill COVID-19 patients in lower-and-middle-income settings, where timely access to emergency care and accurate diagnostic testing is not widely available. Therefore, rapid microbiological diagnosis is essential to improve effective therapy delivery to affected individuals, preventing adverse outcomes and reducing antimicrobial resistance. Methods: We conducted a cross-sectional study of patients with suspected VAP and COVID-19, evaluating the diagnostic performance of the BioFire® FilmArray® Pneumonia Panel (FA-PP). Respiratory secretion samples underwent standard microbiological culture and FA-PP assays, and the results were compared. ©BMC Infectious DiseasesenAntimicrobial ResistanceBioFire®FilmArray®Pneumonia PanelCOVID-19Syndromic panelsVentilator-Associated PneumoniaResource Types::text::journal::journal article